SCHEMBL1298433

SCHEMBL1298433

O=S(=O)(O)C=CCCCCCCCCCCCCO

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.33
PPARA Q07869 2/20 0.32
EPHX2 P34913 1/20 0.32
GPR84 Q9NQS5 1/20 0.31
FFAR1 O14842 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9875582 1.00 CNR1 (0.33) CNR1PPARAEPHX2GPR84FFAR1
SCHEMBL18091460 0.98 CNR1 (0.34) CNR1
SCHEMBL9150029 0.98 CNR1 (0.34) CNR1
SCHEMBL3504100 0.83 EPHX2 (0.34) EPHX2
SCHEMBL7169009 0.80
SCHEMBL12164294 0.80
SCHEMBL4890657 0.80 PPARA (0.52) PPARAEPHX2
SCHEMBL3308963 0.80 PPARA (0.52) PPARAEPHX2
SCHEMBL11505457 0.80 PPARA (0.52) PPARAEPHX2
SCHEMBL10962186 0.80 PPARA (0.52) PPARAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125504-A1 ORGANOSILICONE MATERIAL AND LATEX COMPOSITION COMPRISING THE SAME MOMENTIVE PERFORMANCE MAT INC (US) 2026-05-07 US disclosed
EP-4399251-A1 AQUEOUS SURFACE TREATING COMPOSITION Momentive Performance Materials Inc. (US) 2024-07-17 EP disclosed
US-20230079912-A1 AQUEOUS SURFACE TREATING COMPOSITION MOMENTIVE PERFORMANCE MATERIALS INC. 2023-03-16 US disclosed
WO-2023038857-A1 AQUEOUS SURFACE TREATING COMPOSITION MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2023-03-16 WO disclosed
US-10716748-B2 Method of treating hair MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2020-07-21 US disclosed
EP-2563328-B1 METHOD OF TREATING DAMAGED HAIR WITH AN AMINOSILICONE MOMENTIVE PERFORMANCE MAT INC (US) 2014-12-17 EP disclosed
US-8440175-B2 Hair cosmetic composition MOMENTIVE PERFORMANCE MATERIALS JAPAN LLC (JP) 2013-05-14 US disclosed
EP-2563328-A2 METHOD OF TREATING DAMAGED HAIR WITH AN AMINOSILICONE Momentive Performance Materials Inc. (US) 2013-03-06 EP disclosed
WO-2011139265-A2 METHOD OF TREATING HAIR MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2011-11-10 WO disclosed
US-20110268681-A1 METHOD OF TREATING HAIR MOMENTIVE PERFORMANCE MATERIALS INC. 2011-11-03 US disclosed
US-20100028287-A1 Hair cosmetic composition MOMENTIVE PERFORMANCE MATERIALS JAPAN LLC (JP) 2010-02-04 US disclosed
US-20080317796-A1 HAIR CARE COSMETIC COMPOSITION GE TOSHIBA SILICONES CO., LTD. 2008-12-25 US disclosed
EP-1380282-B1 COSMETIC HAIR PREPARATION COMPOSITION GE TOSHIBA SILICONES CO LTD (JP) 2005-11-30 EP disclosed
US-20040131570-A1 Cosmetic hair preparation composition MOMENTIVE PERFORMANCE MATERIALS INC. 2004-07-08 US disclosed
EP-1380282-A1 COSMETIC HAIR PREPARATION COMPOSITION GE TOSHIBA SILICONES CO., LTD. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080317796-A1 HAIR CARE COSMETIC COMPOSITION H1-0, H1-4, H1-2 CNR1 2328/4885PPARA 4331/4885EPHX2 2493/4885
US-20040131570-A1 Cosmetic hair preparation composition H1-0, H1-4, SRM CNR1 1965/4885PPARA 4242/4885EPHX2 1934/4885
US-20260125504-A1 ORGANOSILICONE MATERIAL AND LATEX COMPOSITION COMPRISING THE SAME H1-0, MSR1, H1-10 CNR1 126/4885PPARA 4409/4885EPHX2 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.